Mutations in CLDN2 Are Not a Common Cause of Pediatric Idiopathic Hypercalciuria in Canada

Abstract

French

Background:

Hypercalciuria is the most common risk factor for kidney stone formation, including in pediatric patients. However, the etiology is often unknown and children are frequently diagnosed with idiopathic hypercalciuria. Nearly 50% of children with hypercalciuria have a first-degree relative with kidney stones, suggesting a strong genetic basis for this disease. A failure of calcium reabsorption from the proximal nephron is implicated in the pathogenesis of hypercalciuria. Claudin-2 is a tight junction protein abundantly expressed in the proximal tubule. It confers paracellular permeability to calcium that is essential for transport across the proximal tubule where the majority of filtered calcium is reabsorbed.

Objective:

Our objective was to examine the frequency of coding variations in CLDN2 in a cohort of children with idiopathic hypercalciuria.

Design:

Mixed method including retrospective chart review and patient interview, followed by genetic sequencing.

Setting:

Three tertiary care centers in Canada.

Patients:

Children (age 1-18 years) with idiopathic hypercalciuria. Patients with other causes of hypercalciuria were excluded.

Methods:

Data were collected from 40 patients with idiopathic hypercalciuria. Informed consent to collect DNA was obtained from 13 patients, and the final and only coding exon of CLDN2 was sequenced.

Results:

The majority of patients were male, white, and had a positive family history of kidney stones. Parathyroid hormone levels were significantly lower than the reference range (P < .001). The levels of 1,25-dihydroxyvitamin D were also significantly higher in our patient cohort, relative to the reference range (P < .001). Sequence analysis of CLDN2 did not identify any coding variations.

Limitations:

Sequencing analysis was limited to the final coding exon and small sample size.

Conclusions:

CLDN2 coding variations are not a common cause of idiopathic hypercalciuria in Canadian children. Further study is needed to determine the causes of hypercalciuria in pediatric patients and develop targeted therapies.

Keywords

children idiopathic hypercalciuria calcium claudin

Introduction

Kidney stone disease causes significant morbidity with a lifetime incidence of 10% in white males.^1-5 The cost of medical intervention and time lost from work is estimated at $10 billion per year in the United States alone.^2,6-8 Furthermore, the prevalence continues to increase across all age groups, including children.^6,9,10 The majority of renal calculi (85%) are composed primarily of calcium, most frequently coupled to oxalate.^2,5 The greatest risk factor for the development of kidney stones is hypercalciuria, which occurs in 40% to 50% of cases.^2,4

Pediatric patients with hypercalciuria often present with heterogeneous, nonspecific symptoms, including recurrent episodes of gross hematuria, persistent microscopic hematuria, or abdominal pain, even in the absence of radiographic kidney stones.^2,10-12 Idiopathic hypercalciuria is also associated with lower urinary tract symptoms, including urinary frequency, dysuria, and enuresis, as well as recurrent urinary tract infections (UTIs).^11-15 Microcrystals and epithelial injury may impair clearance of bacteria from the lower genitourinary tract. Hypercalciuria can be caused by a number of conditions, including hypercalcemia, hyperparathyroidism, vitamin D intoxication, distal renal tubular acidosis, other genetic syndromes (e.g., Williams or Bartter syndromes), and by medications, including furosemide or prednisone.^2,10,16 However, the majority of patients do not have one of these diagnoses and instead are labeled as having idiopathic hypercalciuria.

A failure to reabsorb filtered calcium plays a critical role in the pathogenesis of hypercalciuria. Most calcium reabsorption occurs in the proximal tubule via passive paracellular transport. Claudins are tight junction proteins that form paracellular pores and barriers across epithelia of the body.^17-19 Different claudin isoforms exhibit different patterns of expression along the nephron. The localization of many of the claudins in the kidney has largely been determined, although their physiologic roles continue to be described. Their primary role is to regulate paracellular transport of small ions and several are known to be involved in calcium transport. Mutations in claudin-16 and claudin-19 are implicated in familial hypomagnesemia with hypercalciuria and nephrocalcinosis.^18,20-22 Altered claudin-14 expression likely also plays a role in hypercalciuria.^18,23-27

Claudin-2 is expressed in the proximal nephron and intestine and is preferentially cation permeable.^28-31 Intestinal expression of claudin-2 enables the paracellular absorption of calcium.³⁰ Patients with idiopathic hypercalciuria have increased postprandial distal tubular delivery of sodium and calcium, consistent with reduced proximal reabsorption.³² CLDN2 knockout mice (Cldn2^-/-) have hypercalciuria,³³ and a family with missense CLDN2 mutations has hypercalciuria and kidney stones. We thus hypothesized that mutations in CLDN2 in children could also cause hypercalciuria and kidney stone formation. To determine whether mutations in CLDN2 might cause hypercalciuria, we examined this gene in a cohort of Canadian children with idiopathic hypercalciuria and kidney stones.

Methods

Ethics approval was obtained from the University of Alberta (Pro00018459), University of Saskatchewan (Bio 11-126), and University of Toronto (STUDY #: 1000039105). Children with idiopathic hypercalciuria were recruited from outpatient pediatric nephrology clinics at the Stollery Children’s Hospital, Edmonton, Alberta; Jim Pattison Children’s Hospital, Saskatoon, Saskatchewan; and The Hospital for Sick Children, Toronto, Ontario in Canada. Data were collected using retrospective chart review and patient interview. Hypercalciuria was defined as urine calcium:creatinine (Ca:Cr) ratio (mmol:mmol) >2.24 (<6 months), >1.68 (6-12 months), and >0.56 (1-18 years) with the age of the upper limit of urinary calcium in brackets. Patients with abnormal serum calcium, magnesium, phosphorus, or parathyroid hormone (PTH) were excluded. We also calculated PTH percentile (PTH %ile) based on the reported normal range of local laboratories to account for variations in local assays. We collected vitamin D levels, where available. Children with a genetic diagnosis of Bartter syndrome, Dent disease, distal renal tubular acidosis, or Williams syndrome were also excluded, as were those taking corticosteroids or furosemide. Medication data, including vitamin D supplementation, was collected, where available. The data collection form is available in supplementary data (Supplementary Figure 1).

Sequencing of CLDN2 was performed with patient consent, as previously described.²³ In order to sequence CLDN2, genomic DNA was isolated from whole blood using the DNeasy Blood & Tissue Kit (Qiagen Inc, ON, Canada). We then amplified the final and coding exon of human CLDN2 with polymerase chain reaction (PCR) promoters 5′-GCA AGA GCT TCA GCC TGA AGA CAA G-3′ and reverse 5′-CTG TTT TTC ACA GAC CCA GCC ACC-3′. After PCR clean up with the QIAquick PCR purification Kit (Qiagen Inc), the PCR product underwent Sanger sequencing at the Applied Genomics Core, Faculty of Medicine and Dentistry, University of Alberta. The sequence data were analyzed using pairwise sequence alignment software at https://www.ebi.ac.uk/Tools/psa/emboss_needle/.

All analyses were planned a priori and statistical analyses conducted using STATA version 12 (College Station, TX, USA). The data are expressed as mean ± standard deviation. Comparisons were made to local laboratory reference ranges using Wilcoxon signed-rank test, as appropriate, and P value ≤ .05 was considered statistically significant.

Results

We enrolled 40 children with idiopathic hypercalciuria. Patient characteristics are summarized in Table 1. The majority of patients were male (60.0%) and had a positive family history of kidney stones (51.3%). The average age at symptom onset was 5.6 ± 5.1 years. Ethnicity was not known in 50%; but of those identified, 75% (or 37.5% of the overall cohort) were white. The majority of patients had a history of kidney stones (87.5%), defined as either having previously passed a stone and/or radiographic evidence of stone formation. Stone analysis using urine microscopy was completed in 60% of the cohort. The most common kidney stone isolated was calcium oxalate (65.7%), followed by uric acid (20.0%) and calcium phosphate (14.3%).

Table 1.

Patient Characteristics.

Age at symptoms onset (years), mean (SD)	5.6 (5.1)
Male, n (%)	24 (60.0%)
Ethnicity, n (%)
Original peoples	1 (2.5%)
Black or African origin	1 (2.5%)
Asian	1 (2.5%)
White	15 (37.5%)
Middle Eastern	1 (2.5%)
East Indian	1 (2.5%)
Unknown	20 (50%)
History of renal calculi, n (%)	35 (87.5%)
Calcium phosphate	5 (14.3%)
Calcium oxalate	23 (65.7%)
Uric acid	7 (20.0%)
Family history of renal calculi, n (%)	20 (51.3%)
First degree relative	8 (25.0%)
Second degree relative	16 (50.0%)
Investigations at time of diagnosis, mean (SD)
Serum calcium (mmol/L) Normal range: 2.00-2.60 mmol/L	2.46 (0.08)
Serum magnesium (mmol/L) Normal range: 0.70-1.00 mmol/L	0.89 (0.17)
Serum phosphate (mmol/L) Normal range: 0.80-1.45 mmol/L	1.57 (0.25)
Serum total CO₂ (mmol/L) Normal range: 23-31 mmol/L	24 (3)
Urine calcium:creatinine (mmol/mmol) for children >1 year^a Normal range: <0.56 mmol/mmol	1.13 (0.40)
Urine citrate:creatinine (mmol/mmol) Normal range: >0.1 mmol/mmol	0.23 (0.17)
Urine magnesium:creatinine (mol/mol) Normal range: <0.6 mol/mol	0.55 (0.42)
Urine osmolarity (mmol/kg) Normal range: 250-900 mmol/kg	739 (185)
Urine oxalate:creatinine (mmol/mmol) Normal range: <0.08 mmol/mmol	0.06 (0.04)
Urine pH	6.5 (0.8)
Urine urate:creatinine (mol/mol) Normal range: <0.56 mol/mol	0.50 (0.38)

Note. Normal ranges for serum and urine investigations obtained from local lab ranges; if not available, normal ranges obtained from pediatric literature.⁵

Urine Ca:Cr specifically at the time of first presentation was available for 33/40 children. Age at time of first presentation was >1 year (range: 1-15 years) in 30/33 children.

The average urine Ca:Cr ratio was higher than the established normal range, stratified by age (Table 1). The majority of patients presented with hematuria (gross or microscopic) (Figure 1). Nearly 40% of the cohort had recurrent episodes of abdominal pain. Children presented with symptoms of dysuria (28%), recurrent UTIs (19%), or urinary frequency (13%).

Figure 1.

Symptoms at initial presentation.

All patients in our cohort had normal serum calcium, phosphorus, and magnesium levels in order to be diagnosed with idiopathic hypercalciuria. While all children had a normal PTH level, many patients had levels in the lower end of the laboratory-reported normal range. Therefore, we converted PTH levels to PTH %ile using the normal ranges reported by local laboratories. The mean PTH %ile value was 36.1 ± 23.6 (Table 2). The average 25-hydroxyvitamin D level was within normal limits, and no children had elevated 25-hydroxyvitamin D levels (>200 nmol/L). However, median 25-hydroxyvitamin D level was lower than median of the local laboratory range (P < .001). The average 1,25-dihydroxyvitamin D level was elevated at 201.6 pmol/L ± 102.7 (Table 2), and median 1,25-dihydroxyvitamin D level was higher than median of the local laboratory range (P < .001).

Table 2.

PTH and Vitamin D Levels.

	Hypercalciuric cohort^a		Normal range
	Mean (SD)	Median (IQR)	Normal range
PTH %ile	36.1 (23.6)	29.6 (36.2)*	—
25-hydroxyvitamin D (nmol/L)	80.1 (27.3)	83.0 (36.0)*	80-200
1,25-dihydroxyvitamin D (pmol/L)	201.6 (102.7)	160.0 (90.3)*	43-168

Note. Normal range for local laboratory included for reference. PTH %ile = parathyroid hormone percentile (based on reported normal range by local laboratory); IQR = interquartile range.

Of the hypercalciuric cohort (N = 40), 39 children had available PTH measurement, 33 had 25-hydroxyvitamin D measurement, and 20 had 1,25-dihydroxyvitamin D measurement.

P < .001.

Sequence analysis of the final and only coding exon of CLDN2 was performed for 13 patients in the cohort and revealed no single nucleotide variations (SNV) different to the reference sequence.

Discussion

We identified a pediatric cohort with isolated idiopathic hypercalciuria followed at three tertiary centers in Canada. The clinical characteristics of our cohort reflect that reported in the literature.^2,3,9 Patients were diagnosed after presenting with highly variable and nonspecific symptoms. The most common presenting feature was hematuria (including gross and persistent microscopic hematuria). A large proportion of patients presented with persistent abdominal pain and nonspecific urinary symptoms, including dysuria, frequency, urgency, and recurrent UTIs. The majority of patients were male and had a positive family history of kidney stones. The majority of patients had kidney stones, which were composed of calcium oxalate.

Claudin-2 plays an important role in paracellular calcium transport in the renal proximal tubule and colon, as demonstrated by genetic studies and mouse models.^30,32,33 CLDN2 knockout mice have reduced calcium uptake from the colon and reduced renal calcium reabsorption, leading to hypercalciuria and kidney stones. A recent study also identified a CLDN2 mutation in an Iranian family with hypercalciuria and kidney stones.³⁰ Despite its role in the pathogenesis of hypercalciuria, no patients in our cohort had any variation in the coding exon of CLDN2 different to the reference sequence. This is the likely consequence of CLDN2 not harboring any common variations, with the most common variation reported in CLDN2 in the gnomAD browser occurring in less than 0.1% of alleles. It does not appear, therefore, that CLDN2 mutations are a common cause of idiopathic hypercalciuria in Canadian children.

Targeted genetic studies of kidney stone cohorts from stone clinics have previously been performed in order to identify pathogenic mutations.^34-36 Causative mutations were identified in 10% to 30% of the studied cohorts, providing clear evidence that pathogenic mutations are highly prevalent. Identifying heritable causes of kidney stones is also important for prognostic purposes, tailored therapeutics, and potential screening of asymptomatic family members. Although these studies have examined genes in the claudin family (including CLDN16 and CLDN19), the genes studied have been heterogeneous and did not include CLDN2. Therefore, our study, despite being restricted to a single candidate gene and carried out in a smaller cohort, contributes to the existing literature, but should be repeated in larger cohorts.

PTH and vitamin D are key regulators of calcium homeostasis.¹⁶ Vitamin D supplementation has been associated with increased calcium uptake from the gastrointestinal tract, leading to hypercalcemia, hypercalciuria, and kidney stones.³⁷ Meta-analyses have demonstrated a clear association between vitamin D supplementation and hypercalciuria and stone formation in adults and children.^38,39 Several studies have demonstrated elevated 1,25-dihydroxyvitamin D levels in adults with idiopathic hypercalciuria.⁴⁰ In children, CYP24A1 mutation has been shown to cause idiopathic infantile hypercalcemia through deficiency of the enzyme 25-hydroxyvitamin D 24-hydroxylase, which degrades 1,25-dihydroxyvitamin D.⁴¹ In our cohort, PTH levels were within the normal range (as per our inclusion criteria); however, PTH %ile was significantly lower than the median of the local laboratory reference range (P < .001). No children had elevated 25-hydroxyvitamin D levels (>200 nmol/L); however, median 25-hydroxyvitamin D levels were significantly lower, relative to the local laboratory reference range. Average 1,25-dihydroxyvitamin D levels were high and median levels were significantly higher, relative to the local laboratory reference range. These finding suggest that abnormal PTH and vitamin D levels may contribute to hypercalciuria and kidney stone formation in children. However, further studies in larger cohorts are needed.

Our study has several limitations. As we only examined the final coding exon, we cannot exclude mutations in the noncoding exons or intronic regions causing hypercalciuria in our patients. Our study population was relatively homogeneous; of the patients where the ethnicity was known, 75% were white. Thus, we cannot conclude that mutations in CLDN2 may be a cause of hypercalciuria in populations that are not predominantly white. Our study also included patients with clinical criteria of hypercalciuria, but without a first-degree family history of nephrocalcinosis or kidney stones, which likely reduced the sensitivity of screening for candidate genes causing hypercalciuria. However, we felt that reporting of family history was unlikely to be reliable, as often only one parent accompanied their child to appointments. Furthermore, as confirmed by our study findings, hypercalciuria is often associated with a nonspecific presentation and delayed diagnosis. It is possible that elevated urine Ca:Cr levels could be related to low muscle mass and low urinary creatinine excretion. Although we did not specifically assess the muscle mass of children in our cohort, we inquired as to whether children had significant comorbidities including failure to thrive or short stature, which were not reported in any patients. Most of our cohort also had complications of hypercalciuria, which would reduce the likelihood of false positives. Finally, while our study is fairly large by pediatric standards, we are still limited by the small number of patients and controls. Future studies are needed with larger cohorts to confirm our findings that CLDN2 mutations are rare in children with idiopathic hypercalciuria.

Conclusions

We described a cohort of children with idiopathic hypercalciuria. Our patients had significant morbidity, including hematuria, urinary symptoms, abdominal pain, and kidney stones (either on history or radiographic evidence). Coding CLDN2 mutations do not appear to be a common cause of idiopathic hypercalciuria in children in Canada. The role of other claudins as a cause of hypercalciuria is still being examined, with further studies needed.

Supplemental Material

sj-docx-1-cjk-10.1177_20543581221098782 – Supplemental material for Mutations in CLDN2 Are Not a Common Cause of Pediatric Idiopathic Hypercalciuria in Canada

Supplemental material, sj-docx-1-cjk-10.1177_20543581221098782 for Mutations in CLDN2 Are Not a Common Cause of Pediatric Idiopathic Hypercalciuria in Canada by Emma H. Ulrich, Elizabeth Harvey, Catherine J. Morgan, Maury Pinsk, Robin Erickson, Lisa A. Robinson and R. Todd Alexander in Canadian Journal of Kidney Health and Disease

Footnotes

Ethics Approval and Consent to Participate

Ethics approval was obtained from Research Ethics Board at each of the participating institutions: University of Alberta (Pro00018459), University of Saskatchewan (Bio 11-126), and University of Toronto (STUDY #: 1000039105).

Consent for Publication

Written informed consent for publication was also obtained during study visits (from legal guardian for children <18 years).

Availability of Data and Materials

Raw sequencing data was generated at the University of Alberta. Derived data supporting the findings of this study are available from the corresponding author [RTA] on request.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RTA work closely with Dr Hartwig as a member of the KRESCENT leadership team (she is a handling editor).

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by grants from Alberta Innovates Health Solutions (AIHS), the Canadian Institutes of Health Research (CIHR), and the Women and Children Health Research Institute (WCHRI), which is supported by the Stollery Children’s Hospital Foundation, to R.T.A. who is the Canada Research Chair in Renal Epithelial Transport Physiology.

ORCID iDs

Emma H. Ulrich

R. Todd Alexander

Supplemental Material

Supplemental material for this article is available online.

References

Sorokin

Mamoulakis

Miyazawa

Rodgers

Talati

Lotan

Epidemiology of stone disease across the world. World J Urol. 2017;35:1301-1320. doi:10.1007/s00345-017-2008-6.

Coe

Worcester

Evan

AP.

Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016;12:519-533. doi:10.1038/nrneph.2016.101.

Curhan

GC.

Epidemiology of stone disease. Urol Clin North Am. 2007;34:287-293. doi:10.1016/j.ucl.2007.04.003.

Liebman

Taylor

Bushinsky

DA.

Idiopathic hypercalciuria. Curr Rheumatol Rep. 2006;8:70-75. doi:10.1007/s11926-006-0029-z.

Geary

Schaefer

Pediatric Kidney Disease. 2nd ed. Berlin, Germany: Springer; 2005.

Ziemba

Matlaga

BR.

Epidemiology and economics of nephrolithiasis. Investig Clin Urol. 2017;58:299-306. doi:10.4111/icu.2017.58.5.299.

Lotan

Economics and cost of care of stone disease. Adv Chronic Kidney Dis. 2009;16:5-10. doi:10.1053/j.ackd.2008.10.002.

Lotan

Buendia Jimenez

Lenoir-Wijnkoop

, et al. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. BJU Int. 2012;110:E1060-E1067. doi:10.1111/j.1464-410X.2012.11212.x.

Dwyer

Krambeck

Bergstralh

Milliner

Lieske

Rule

AD.

Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol. 2012;188(1):247-252. doi:10.1016/j.juro.2012.03.021.

10.

Srivastava

Schwaderer

Diagnosis and management of hypercalciuria in children. Curr Opin Pediatr. 2009;21:214-219. doi:10.1097/MOP.0b013e3283223db7.

11.

Lau

KK.

Clinical manifestations of pediatric idiopathic hypercalciuria. Front Biosci (Elite Ed). 2009;1:52-59. doi:10.2741/e6.

12.

Schwaderer

Srivastava

Complications of hypercalciuria. Front Biosci (Elite Ed). 2009;1:306-315. doi:10.2741/e30.

13.

Sadeghi-Bojd

Hashemi

Hypercalciuria and recurrent urinary tract infections among children in Zahedan, Iran. J Pak Med Assoc. 2008;58:624-626.

14.

Biyikli

Alpay

Guran

Hypercalciuria and recurrent urinary tract infections: incidence and symptoms in children over 5 years of age. Pediatr Nephrol. 2005;20:1435-1438. doi:10.1007/s00467-005-1892-y.

15.

Mahmoodzadeh

Nikibakhsh

Karamyyar

, et al. Idiopathic hypercalciuria in children with vesico ureteral reflux and recurrent urinary tract infection. Urol J. 2010;7:95-98.

16.

Srivastava

Alon

US.

Pathophysiology of hypercalciuria in children. Pediatr Nephrol. 2007;22:1659-1673. doi:10.1007/s00467-007-0482-6.

17.

Angelow

AS.

Claudins and paracellular transport: an update. Curr Opin Nephrol Hypertens. 2007;16:459-464. doi:10.1097/MNH.0b013e32820ac97d.

18.

Hou

Claudins and mineral metabolism. Curr Opin Nephrol Hypertens. 2016;25:308-313. doi:10.1097/MNH.0000000000000239.

19.

Gunzel

AS.

Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93:525-569. doi:10.1152/physrev.00019.2012.

20.

Viering

DHHM

de Baaij

JHF

Walsh

Kleta

Bockenhauer

. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol. 2017;32:1123-1135. doi:10.1007/s00467-016-3416-3.

21.

Knohl

Scheinman

SJ.

Inherited hypercalciuric syndromes: Dent’s disease (CLC-5) and familial hypomagnesemia with hypercalciuria (paracellin-1). Semin Nephrol. 2004;24(1):55-60. doi:10.1053/j.semnephrol.2003.08.011.

22.

Agus

ZS.

Mechanisms and causes of hypomagnesemia. Curr Opin Nephrol Hypertens. 2016;25:301-307. doi:10.1097/MNH.0000000000000238.

23.

Ure

Heydari

Pan

, et al. A variant in a cis-regulatory element enhances claudin-14 expression and is associated with pediatric-onset hypercalciuria and kidney stones. Hum Mutat. 2017;38:649-657. doi:10.1002/humu.23202.

24.

Plain

Alexander

RT.

Claudins and nephrolithiasis. Curr Opin Nephrol Hypertens. 2018;27:268-276. doi:10.1097/MNH.0000000000000426.

25.

AS.

Claudins and the kidney. J Am Soc Nephrol. 2015;26:11-19. doi:10.1681/asn.2014030284.

26.

Hou

Rajagopal

AS.

Claudins and the kidney. Annu Rev Physiol. 2013;75:479-501. doi:10.1146/annurev-physiol-030212-183705.

27.

Gong

Hou

Claudins in barrier and transport function-the kidney. Pflugers Arch. 2017;469:105-113. doi:10.1007/s00424-016-1906-6.

28.

Muto

Furuse

Kusano

Claudins and renal salt transport. Clin Exp Nephrol. 2012;16:61-67. doi:10.1007/s10157-011-0491-4.

29.

ASL

. Paracellular transport and energy utilization in the renal tubule. Curr Opin Nephrol Hypertens. 2017;26:398-404. doi:10.1097/MNH.0000000000000348.

30.

Curry

Saurette

Askari

, et al. Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J Clin Invest. 2020;130:1948-1960. doi:10.1172/jci127750.

31.

Worcester

Coe

Evan

, et al. Evidence for increased postprandial distal nephron calcium delivery in hypercalciuric stone-forming patients. Am J Physiol Renal Physiol. 2008;295:F1286-F1294. doi:10.1152/ajprenal.90404.2008.

32.

Muto

Hata

Taniguchi

, et al. Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl Acad Sci U S A. 2010;107:8011-8016. doi:10.1073/pnas.0912901107.

33.

Raju

Shashikanth

Tsai

, et al. Inactivation of paracellular cation-selective claudin-2 channels attenuates immune-mediated experimental colitis in mice. J Clin Invest. 2020;130:5197-5208. doi:10.1172/JCI138697.

34.

Daga

Majmundar

Braun

, et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int. 2018;93:204-213. doi:10.1016/j.kint.2017.06.025.

35.

Braun

Lawson

Gee

, et al. Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol. 2016;11:664-672. doi:10.2215/CJN.07540715.

36.

Halbritter

Baum

Hynes

, et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol. 2015;26:543-551. doi:10.1681/ASN.2014040388.

37.

Ganji

Shafii

Hakemi

MS.

Vitamin D supplementation and risk of hypercalciuria in stone formers. Iran J Kidney Dis. 2019;13:27-31.

38.

Malihi

Stewart

, et al. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. 2016;104:1039-1051. doi:10.3945/ajcn.116.134981.

39.

Vogiatzi

Jacobson-Dickman

DeBoer

; Drugs and Therapeutics Committee of The Pediatric Endocrine Society. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. J Clin Endocrinol Metab. 2014;99:1132-1141. doi:10.1210/jc.2013-3655.

40.

Letavernier

Daudon

Vitamin D, hypercalciuria and kidney stones. Nutrients. 2018;10:366. doi:10.3390/nu10030366.

41.

Schlingmann

Kaufmann

Weber

, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365:410-421. doi:10.1056/NEJMoa1103864.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB